CD4 and colitis: Ozanimod was shown to induce the internalization and degradation of these receptors, improve the histological score in mice with TNBS (and adoptive CD4+CD45RB+T-cell transfer mediated) colitis and reduce the numbers of circulating B and CCR7+ T-lymphocytes [176].